You are not logged in.

Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.

Wynchank,D and Berk,M 2003, Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial., Human Psychopharmacology, vol. 18, no. 4, pp. 271-275, doi: 10.1002/hup.476.

Attached Files
Name Description MIMEType Size Downloads

Title Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Author(s) Wynchank,D
Berk,MORCID iD for Berk,M orcid.org/0000-0002-5554-6946
Journal name Human Psychopharmacology
Volume number 18
Issue number 4
Start page 271
End page 275
Publisher Wiley
Place of publication England
Publication date 2003-06
ISSN 0885-6222
Keyword(s) Science & Technology
Social Sciences
Life Sciences & Biomedicine
Clinical Neurology
Pharmacology & Pharmacy
Psychiatry
Psychology
Neurosciences & Neurology
PSYCHIATRY, SCI
nefazodone
extrapyramidal side effects
parkinsonism
akathisia
5-HT2 ANTAGONIST RITANSERIN
INDUCED AKATHISIA
MIRTAZAPINE
ANTIDEPRESSANT
PHARMACOLOGY
SYMPTOMS
DRUG
Summary Many atypical antipsychotics show antagonism at both serotonergic and dopaminergic neurones and show fewer extrapyramidal side effects (EPS). Nefazodone blocks postsynaptic 5HT2A receptors and weakly inhibits serotonin reuptake. This study aimed to elucidate the role of nefazodone in the treatment of antipsychotic-induced EPS. The trial was a double-blind, randomised, placebo-controlled trial of patients requiring antipsychotic treatment with haloperidol 10mg daily; from which a subgroup of patients who developed EPS were selected for the study. Patients were randomised to add-on therapy with either placebo (n=24) or nefazodone (n=25) 100mg bd. EPS were measured on days 0, 3 and 7 using the Simpson Angus, Barnes akathisia, abnormal involuntary movement and Chouinard scales. Nefazodone significantly reduced EPS as measured by both the Simpson Angus scale and CGI (p=0.007 and 0.0247, respectively). Akathisia and tardive dyskinesia did not differ between the two groups (p=0.601; p=0.507, respectively). These results suggest the role of 5HT2 antagonism in the mechanism of action of atypical antipsychotics with respect to lowering rates of drug-induced EPS. In addition, a therapeutic role for nefazodone is suggested in the treatment of antipsychotic-induced EPS.
Language eng
DOI 10.1002/hup.476
Field of Research 0 Not Applicable
Socio Economic Objective 0 Not Applicable
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2003, Wiley
Persistent URL http://hdl.handle.net/10536/DRO/DU:30071309

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 188 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 18 Mar 2015, 10:13:29 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.